CelcuityFRA:7VR +4.02%11 EBIT per Share is €-3.01 as of Mar. 2026. GuruFocus rates FRA:7VR with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,174 Biotechnology companies, Celcuity ranks worse than 81.77% on this metric.
Celcuity's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.74.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.01.
During the past 3 years, the average EBIT per Share Growth Rate was -13.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -25.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -26.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Celcuity's EBIT per Share or its related term are showing as below:
FRA:7VR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -49.6 Med: -22.7 Max: -5.3
Current: -13
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Celcuity was -5.30% per year. The lowest was -49.60% per year. And the median was -22.70% per year.
FRA:7VR's 3-Year EBIT Growth Rate is ranked worse than 81.77% of 1174
companies
in the Biotechnology industry
Industry Median: 15.4
vs FRA:7VR: -13.00
Celcuity's EBIT for the
three
months ended in Mar. 2026 was €-40.44 Mil.
Celcuity (FRA:7VR) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Celcuity EBIT per Share Related Terms
Celcuity EBIT per Share Historical Data
* Premium members only.
The historical data trend for Celcuity's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celcuity (FRA:7VR) has a EBIT per Share of €-3.01 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Celcuity and its competitors. According to the industry distribution chart, Celcuity ranks #960 out of 1174 companies in the Biotechnology industry, placing it in the top 81.8%.
Is Celcuity's EBIT per Share too high?
Celcuity's current EBIT per Share is €-3.01. Based on the distribution chart, Celcuity ranks #960 out of 1174 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celcuity has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's EBIT per Share compare to ERAS and TNGX?
According to the Biotechnology industry distribution chart, Celcuity ranks #960 out of 1174 companies for EBIT per Share. This places Celcuity in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Celcuity and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celcuity's current EBIT per Share is €-3.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current EBIT per Share of €-3.01. The current EBIT per Share is €-3.01. Celcuity's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current EBIT per Share is €-3.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
11GF Score
Get the complete analysis for FRA:7VR
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VR has been successfully added to your 
